10:35 AM EDT, 07/02/2025 (MT Newswires) -- BriaCell Therapeutics ( BCTX ) was edging up on Wednesday after saying it is adding two large cancer centers in the U.S., to its Phase 3 clinical study which is evaluating its lead clinical candidate, Bria-IMT, plus immune check point inhibitor, versus physician's choice in advanced metastatic breast cancer (MBC).

The Los Angeles Cancer Network and Smilow Cancer Hospital at New Haven, each with 15 satellite locations, will now participate in the study. BriaCell anticipates completing patient enrollment in late 2025 or early 2026 and may report top line data as early as the first half of next year.

"Clinical investigator interest in our Phase 3 study has exceeded our expectations which has significantly expanded patient access to our treatment," said Giuseppe Del Priore, BriaCell's chief medical officer. "This strong engagement reflects both the urgent unmet need in metastatic breast cancer and the dedication of our clinical partners."

Interim data will be analyzed once 144 patient events (deaths) occur, comparing the overall survival in patients treated with the Bria-IMT combination regimen versus those treated with physician's choice as the primary endpoint, a statement added.

Positive results of the pivotal Phase 3 study could result in full approval and marketing authorization for Bria-IMT in MBC patients. BriaCell recently announced positive Phase 2 survival data in a similar MBC patient population treated with the same Bria-IMT combination regimen. The Bria-IMT combination regimen has received FDA Fast Track designation.

BriaCell was last seen up $0.05, to $4.05, on the Toronto Stock Exchange, but is trading at the lower end of its 52 week trading range.

Price: 4.05, Change: +0.05, Percent Change: +1.25